ODevelops medicines for rare neurological disorders such as Angelman syndrome, Fragile X syndrome, and CDKL5 deficiency disorder. The company translates discoveries from human genetics and cellular biology into therapies through research and development, then advances them through clinical trials and regulatory approvals to reach patients. Its products work by targeting specific genetic or cellular pathways that underlie these conditions, aiming to improve neurological function and quality of life. Compared with others in biotech, it differentiates itself by a science-driven, patient-focused approach that closely collaborates with rare disease communities and pursues partnerships and licensing to bring therapies to market. The goal is to deliver safe, effective treatments for patients who have few or no options today and to improve outcomes through validated, life-changing medicines.
Work here?Claim your company
We're working on gathering enough insights on this company, check back soon!
Industries
Company Size
11-50
Company Stage
IPO
Headquarters
New York City, United States
Founded
2014
See people who can refer or advise you
Total Funding
$529.9M
Above
Industry Average
Funded Over
9 Rounds
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
We're working on gathering enough insights on this company, check back soon!
Industries
Company Size
11-50
Company Stage
IPO
Headquarters
New York City, United States
Founded
2014
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs